- Home
- CPT vs ILMN Comparison
CPT vs ILMN Comparison
Compare CPT & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPT
- ILMN
- Stock Information
- Founded
- CPT 1993
- ILMN 1998
- Country
- CPT United States
- ILMN United States
- Employees
- CPT N/A
- ILMN N/A
- Industry
- CPT Real Estate Investment Trusts
- ILMN Medical Specialities
- Sector
- CPT Real Estate
- ILMN Health Care
- Exchange
- CPT Nasdaq
- ILMN Nasdaq
- Market Cap
- CPT 12.6B
- ILMN 13.1B
- IPO Year
- CPT 1993
- ILMN 2000
- Fundamental
- Price
- CPT $115.58
- ILMN $90.49
- Analyst Decision
- CPT Buy
- ILMN Buy
- Analyst Count
- CPT 18
- ILMN 16
- Target Price
- CPT $129.89
- ILMN $126.38
- AVG Volume (30 Days)
- CPT 852.7K
- ILMN 2.0M
- Earning Date
- CPT 07-31-2025
- ILMN 08-05-2025
- Dividend Yield
- CPT 3.62%
- ILMN 3.42%
- EPS Growth
- CPT N/A
- ILMN N/A
- EPS
- CPT 1.09
- ILMN N/A
- Revenue
- CPT $1,562,268,000.00
- ILMN $4,337,000,000.00
- Revenue This Year
- CPT $2.48
- ILMN N/A
- Revenue Next Year
- CPT $3.26
- ILMN $3.11
- P/E Ratio
- CPT $106.26
- ILMN N/A
- Revenue Growth
- CPT 0.55
- ILMN N/A
- 52 Week Low
- CPT $102.35
- ILMN $68.70
- 52 Week High
- CPT $127.69
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- CPT 45.83
- ILMN 65.11
- Support Level
- CPT $115.08
- ILMN $88.65
- Resistance Level
- CPT $116.86
- ILMN $91.57
- Average True Range (ATR)
- CPT 2.02
- ILMN 2.68
- MACD
- CPT -0.21
- ILMN 0.54
- Stochastic Oscillator
- CPT 20.28
- ILMN 91.55
About CPT Camden Property Trust
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 177 multifamily properties comprised of nearly 59,996 apartment homes across the United States.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.